Maze Therapeutics (MAZE) Other Working Capital Changes (2024 - 2026)
Maze Therapeutics (MAZE) posted Other Working Capital Changes of $18000.0 for Q1 2026, down 99.27% sequentially from $2.5 million in Q4 2025, and up 102.24% YoY from $8900.5 in Q1 2025.
Powered by 
Analysis
Maze Therapeutics (MAZE) Other Working Capital Changes (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Other Working Capital Changes for 3 years, with the latest figure at $18000.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 102.24% year-over-year to $18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $844000.0 (up 372.26% YoY) and the FY2025 annual result came in at $21000.0, down 96.36% from the prior year.
- Other Working Capital Changes retreated to $18000.0 in Q1 2026 per MAZE's latest filing, from $2.5 million in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $3.3 million in Q4 2025 and troughed at -$2.1 million in Q3 2025.
- A 3-year average of $537888.9 and a median of $474000.0 in 2025 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 1170.77% in 2025, down 1081.71% in 2025.
- Over 3 years, Other Working Capital Changes stood at $2.7 million in 2024, then fell by 8.94% to $2.5 million in 2025, then sank by 99.27% to $18000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered $18000.0, $2.5 million, and -$2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Maze Therapeutics | 1.55 Bn | 1.55 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -928,000.00 |
| Jun 30, 2026 | -928,000.00 |
| Mar 31, 2026 | -915,000.00 |
| Mar 31, 2026 | -915,000.00 |
| Dec 31, 2025 | -5.83 Mn |
| Dec 31, 2025 | -5.83 Mn |
| Sep 30, 2025 | 758,000.00 |
| Sep 30, 2025 | 758,000.00 |
| Jun 30, 2025 | 2.56 Mn |
| Jun 30, 2025 | 2.56 Mn |
| Mar 31, 2025 | -805,000.00 |
| Mar 31, 2025 | -805,000.00 |
| Dec 31, 2024 | -784,000.00 |
| Dec 31, 2024 | -784,000.00 |
| Sep 30, 2024 | -720,000.00 |
| Sep 30, 2024 | -720,000.00 |
| Jun 30, 2024 | -297,000.00 |
| Jun 30, 2024 | -297,000.00 |
| Mar 31, 2024 | -1.11 Mn |
| Mar 31, 2024 | -1.11 Mn |